IKT
Inhibikase Therapeutics Inc

1,889
Loading...
Loading...
News
all
press releases
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc...
Globe Newswire·1y ago
News Placeholder
More News
News Placeholder
Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...
Simply Wall St·1y ago
News Placeholder
Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
Related Stocks: NAS:IKT...
GuruFocus·1y ago
News Placeholder
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript...
Seeking Alpha: Transcripts·1y ago
News Placeholder
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript...
SeekingAlpha·1y ago
News Placeholder
Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line
Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line...
SeekingAlpha.com: All News·1y ago
News Placeholder
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or...
Globe Newswire·1y ago
News Placeholder
Inhibikase Therapeutics to provide trial update for Risvodetinib
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company developing protein kinase...
Globe Newswire·2y ago
News Placeholder
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylateBOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc...
Globe Newswire·2y ago

Latest IKT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.